BAYER AKTIENGESELLSCHAFT «...1112131415...» Page 15 out of 137 from 01/07/1988 to 16/08/2024 The price-sensitive information presented in other languages is a literal translation of the price-sensitive information stated in Spanish 04/12/2017 20:16 BAYER AKTIENGESELLSCHAFT R&D: new licenses, patents and registered trademarks Updated larotrectinib pediatric clinical trial data demonstrate continued durability of response in TRK fusion cancers Register number: 259176 01/12/2017 14:10 BAYER AKTIENGESELLSCHAFT Mergers, splits, dissolutions and spin-offs CFIUS completes review of proposed merger of Bayer and Monsanto Register number: 259080 01/12/2017 14:03 BAYER AKTIENGESELLSCHAFT R&D: new licenses, patents and registered trademarks Bayer: Phase III trial of radium-223 dichloride in combination with abiraterone acetate and prednisone/prednisolone for patients with metastatic castration-resistant prostate cancer unblinded early Register number: 259079 24/11/2017 18:09 BAYER AKTIENGESELLSCHAFT R&D: new licenses, patents and registered trademarks ): Phase III study program with Amikacin Inhale in addition to standard of care in intubated and mechanically ventilated patients with Gram-negative pneumonia does not meet primary endpoint of superiority Register number: 258860 15/11/2017 11:27 BAYER AKTIENGESELLSCHAFT Composition of the board of directors Heiko Schipper to join Bayer Board of Management and head Consumer Health Division Register number: 258544 14/11/2017 14:22 BAYER AKTIENGESELLSCHAFT R&D: new licenses, patents and registered trademarks Bayer and Loxo Oncology to develop and commercialize two novel oncology therapies selectively targeting genetic drivers of cancer Register number: 258504 06/11/2017 18:47 BAYER AKTIENGESELLSCHAFT R&D: new licenses, patents and registered trademarks Bayer submits application for marketing approval of rivaroxaban for patients with coronary or peripheral artery disease to European Medicines Agency Register number: 258264 30/10/2017 19:21 BAYER AKTIENGESELLSCHAFT R&D: new licenses, patents and registered trademarks Bayer receives FDA approval for Xarelto® 10 mg once daily for the extended treatment of venous thromboembolism Register number: 258007 26/10/2017 15:02 BAYER AKTIENGESELLSCHAFT Information on P&L Bayer: Public Information refered to Q3-2017 Register number: 257864 26/10/2017 14:57 BAYER AKTIENGESELLSCHAFT Information on P&L Bayer: Sales and earnings increased Register number: 257862 Page 15 out of 137 «...1112131415...»